Definium's LSD pill shows significant anxiety reduction in Phase 3 trial
Definium Therapeutics announced results of a Phase 3 trial testing its LSD‑based pill DT120 in patients with generalized anxiety disorder.
The study enrolled 214 participants who received a single dose of DT120 or a placebo, and the company reported a statistically significant reduction in anxiety symptoms compared with placebo.
This is the first of two large trials planned for the anxiety indication and follows a recent Phase 3 success in major depression, underscoring the firm’s progress in psychedelic therapeutics.
The positive data may pave the way for further regulatory discussions and potential market entry, pending results from the upcoming trial.
This writeup was produced by pharmadog from original reporting by STAT.
Original headline: “STAT+: Definium Therapeutics says its LSD therapy eased anxiety in late-stage trial”
read at STAT ↗
comments(0)
5-min edit window · permanent after that